Clinical Trial Update: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [Phase 3]

View source ↗

Summary

Long-term efficacy and safety extension study of BMN 110 in Morquio A syndrome (MPS IVA) completed Phase 3 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morquio Syndrome
• Mucopolysaccharidosis Iva

Drugs mentioned

• BMN 110

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis IV A, Morquio A Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2017-05-19